Tuesday’s Top Wall Street Upgrades and Downgrades: Applied Materials, CVS Health, Hawaiian Electric Industries, Walmart and More

The futures were higher, after a solid start to the new trading week that saw the Nasdaq and the S&P 500 close higher, while the Dow Jones industrials closed lower. As is customary, the Kansas City Federal Reserve will host the Jackson Hole Wyoming Symposium for its annual summer boondoggle this week with assorted Wall Street and Washington big shots. It is a pretty solid bet across Wall Street that in his speech on Friday at the event, Fed Chair Jay Powell will be stressing the “higher for longer” mantra for interest rates. With energy prices rising there is an excellent possibility at this point that the consumer price index inflation numbers for August come in higher than expected when they are released next month. If that is indeed the case, it is likely that rates go higher by 25 basis points at the next Fed meeting in late September.

Treasury yields were higher across the curve on Monday, as traders also will be closely monitoring Powell’s speech this week. One thing is for sure: with interest rates trending higher, and mortgage rates at their highest level since 2002 (the 30-year mortgage rate closed on Friday at 7.06%), the economy is close to hitting the wall. The 10-year note ended Monday at 4.34%, while the two-year paper was last seen at 4.97%. The almost year-long inversion suggests recession in 2024 to many.

Brent and West Texas Intermediate crude both finished the day modestly higher. Once again, the oil rig count reportedly dropped last week, as 12 fewer rigs were operating. Baker Hughes estimates that a stunning 135 rigs are out of commission over the past year. The recent rig count is 54 less than in 2019, before the pandemic started. Brent finished Monday’s session at $84.55, while WTI was last seen at $80.81. Natural gas closed at $2.60.

Gold was barely higher Monday, as a slow summer for the bullion continues. Friday’s positive day ended nine consecutive losing sessions. The closing price for the December contract on Monday was reported at $1,923.80. Bitcoin, which has been pounded this summer, closed Monday flat at $26,096.10.

24/7 Wall St. reviews dozens of analyst research reports each weekday with a goal of finding fresh ideas for investors and traders alike. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. Consensus analyst target data is from Refinitiv.

These are the top Wall Street analyst upgrades, downgrades and initiations seen on Tuesday, August 22, 2023.

AlloVir Inc. (NASDAQ: ALVR): BofA Securities started coverage with a Buy rating and a $17 target price. The consensus target is higher at $20.67. The stock closed 28% higher on Monday at $3.64. Some cited short covering as one reason for the gain.

Applied Materials Inc. (NASDAQ: AMAT): TD Cowen reiterated an Outperform rating and lifted its $150 target price to $160. The consensus target is just $143.44. Monday’s $148.77 close was up over 4% for the day. Strong earnings last week and a solid tailwind for the sector were a catalyst.

Bill Holdings Inc. (NYSE: BILL): BMO Capital Markets reiterated a Market Perform rating but trimmed its $120 target price to $116. The consensus target is $130.43. The shares closed on Monday at $107.53, which was down 3% on the day.

ALSO READ: Oil May Explode Higher to $90 or More: 7 ‘Strong Buy’ Dividend Leaders to Grab Before It’s Too Late

Blue Bird Corp. (NASDAQ: BLBD): BofA Securities initiated coverage with a Buy rating and a $26.50 target price. The consensus target is $29.67. Monday’s final trade was for $21.77 a share.

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX): Truist Financial reiterated a Buy rating. The firm’s $24 target price compares with a consensus of $23 and Monday’s close at $14.60.

Children’s Place Inc. (NASDAQ: PLCE): When Monness Crespi & Hardt reiterated a Buy rating on the shares, its $30 target price rose to $36. The consensus target is $28.75. The stock closed on Monday at $27.86.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS): Oppenheimer started coverage with an Outperform rating and a $7 target price. The $6.90 consensus target is also well above Monday’s $2.20 close.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Source: Read Full Article